IL12/23 blockade for refractory immune-mediated colitis: 2-center experience Journal Article

   


Authors: Shirwaikar Thomas, A.; Lee, S. E.; Shatila, M.; De Toni, E. N.; Török, H. P.; Ben Khaled, N.; Powell, N.; Weight, R.; Faleck, D. M.; Wang, Y.
Article Title: IL12/23 blockade for refractory immune-mediated colitis: 2-center experience
Abstract: INTRODUCTION:Immune checkpoint inhibitor-mediated colitis (IMC) is commonly managed with steroids and biologics. We evaluated the efficacy of ustekinumab (UST) in treating IMC refractory to steroids plus infliximab and/or vedolizumab.RESULTS:Nineteen patients were treated with UST for IMC refractory to steroids plus infliximab (57.9%) and/or vedolizumab (94.7%). Most of them had grade ≥3 diarrhea (84.2%), and colitis with ulceration was present in 42.1%. Thirteen patients (68.4%) attained clinical remission with UST, and mean fecal calprotectin levels dropped significantly after treatment (629 ± 101.5 mcg/mg to 92.0 ± 21.7 mcg/mg, P = 0.0004).DISCUSSION:UST is a promising therapy for the treatment of refractory IMC. © 2023 Wolters Kluwer Health. All rights reserved.
Keywords: adult; clinical article; aged; diarrhea; drug efficacy; follow up; melanoma; metastasis; breast cancer; cohort analysis; lung cancer; steroid; urogenital tract cancer; head and neck cancer; colitis; ulcerative colitis; toxicity; immunosuppressive treatment; endoscopy; interleukin 12; programmed death 1 ligand 1; refractory; interleukin 23; infliximab; interleukin-12; immune checkpoint inhibitor; cancer; humans; human; male; female; article; vedolizumab; calgranulin; ustekinumab; immune-mediated colitis; refractory immune mediated colitis
Journal Title: American Journal of Gastroenterology
Volume: 118
Issue: 9
ISSN: 0002-9270
Publisher: Wolters Kluwer Health  
Date Published: 2023-09-01
Start Page: 1679
End Page: 1683
Language: English
DOI: 10.14309/ajg.0000000000002332
PUBMED: 37216614
PROVIDER: scopus
PMCID: PMC11098450
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85169183094&doi=10.14309%2fajg.0000000000002332&partnerID=40&md5=ae34b04c3bb77d3654734a1122078785
Notes: Article -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. David M. Faleck
    50 Faleck
  2. Seung Eun Lee
    3 Lee
Related MSK Work